A Record Quarter and a Product Launch: Caris Pivots to Early Detection

Caris Life Sciences delivers 45% revenue growth, launches Caris Detect MCED, and raises guidance as volume acceleration and a shift toward early interception define the quarter.

CAI · Earnings Call · 2026-08-05

A Record Quarter and ReAcceleration in Clinical Volume

Caris Life Sciences reported a stellar Q2 2026: total revenue of $263.7 million, up 45% year-over-year, driven by molecular profiling revenue of $252.3 million (up 55%). More important than the number was the narrative: record clinical volume, with 59,200 completed cases (up 18% YoY) including a record sequential addition of 6,400 cases. “This was a record quarter with record clinical volume, including record tissue and record blood volume as the investment in our commercial engine in Q1 has started to pay dividends and will continue into the second half of the year.” — David Halbert, Founder, Chairman and Chief Executive Officer · 2026-08-05 The commercial realignment from Q1 is clearly paying off, as the sales force expansion from 82 to 146 territories is generating momentum. Management had telegraphed the reacceleration in the prior call; as CFO Luke Power noted in May: “And those cases will flow through in the second quarter, and it will be caught up by the end of the second quarter as we progress into the second half of the year.” — Luke Power, Chief Executive Officer · 2026-05-07 That promise has been kept.

The Product Pivot: Early Detection and the Mutational Cleanse

The quarter also marked the launch of Caris Detect, the company's multi-cancer early detection (MCED) test, which leverages Whole Genome and Whole Transcriptome sequencing. This is a fundamental shift from the company's core therapy-selection business toward a broader patient journey. David Halbert framed it as a comprehensive approach: “Why settle for a test that looks for a single cancer when one blood draw can look for many, currently 58 so far and actually perform where it counts early.” — David Halbert, Founder, Chairman and Chief Executive Officer · 2026-08-05 The company is pairing detection with what it calls a "mutational cleanse"—using AI to identify immunogenic mutations and build personalized immune targets, effectively moving from early detection to early interception. David Spetzler described the arc: “Find the dangerous clone early, make its mutation visible to the immune system and remove it before clinically overt disease ever emerges. That is early detection becoming <keyword id="9f5b3b89e1">early interception</keyword>.” — David Spetzler, President · 2026-08-05 This is a genuinely novel approach that leverages the company's proprietary database of over 1.1 million patients. The launch is already generating enthusiasm, and management admits demand may outpace supply, with plans to aggressively scale capacity.

Our current capacity is about $1 billion a year of revenue, and we're just about to triple that. So that will be about $3 billion a year in revenue, and we're still worried about back orders.
David Halbert, Founder, Chairman and Chief Executive Officer · 2026-08-05

Financial Momentum and Guidance

The revenue growth translated directly into profitability. Adjusted EBITDA of $55.7 million and positive free cash flow of $6.4 million marked the fifth consecutive quarter of positive EBITDA and FCF. Gross margins expanded to 68% GAAP (from 63% a year ago). The company raised its full-year revenue guidance to $1.03–1.04 billion (27–28% growth), up from a prior $1.0–1.02 billion. “We had a strong second quarter with total revenue increasing 45% year-over-year to $263.7 million.” — Brian Brille, Vice Chairman and Executive Vice President · 2026-08-05 Luke Power emphasized that the guidance raise is purely driven by the existing molecular profiling business, with no contribution assumed from Caris Detect in the near term. This discipline is a positive; management is investing behind the launch but not counting on it yet. The fundamentals support the acceleration: Total revenue climbed to $216M in Q1 2026, up 79% year-over-year, and the Q2 call shows that momentum continued, with $263.7M in the quarter. The company also projects a significant capacity expansion, potentially tripling from a current ~$1B annual revenue run-rate capacity. The earlier investment in the liquid biopsy specialist team is paying off—as Bobby Hill noted in May: “We expanded our liquid product specialist team before Q1-individuals highly skilled at helping the appropriate patients get blood testing. We saw 135% growth in their targets quarter-over-quarter.” — Bobby Hill, Chief Commercial Officer · 2026-05-07 That focus is now reflected in the 50% year-over-year growth of Caris Assure volume.

Outlook: A Platform Reaching Inflection

Caris is increasingly positioning itself not just as a diagnostics company but as a precision-medicine platform spanning therapy selection, early detection, and future monitoring (MRD is slated for later this year). The pricing power is evident—blended ASP exceeded $3,850, a record—and covered lives for MI Cancer Seek and Caris Assure are growing (239.5M and 131.9M respectively). The planned FDA submission for the blood-based Caris Assure is also a catalyst. The stock has responded: the recent 90-day tape shows a +45.5% return, with a sharp +61% two-week move, reflecting investor enthusiasm for the new product cycle.

The Bottom Line

This quarter answered the key question from the prior call: would the commercial reorganization and new product launches reaccelerate growth? The answer is a resounding yes. Caris is executing on an ambitious roadmap that combines strong core growth with a transformative Early Detection offering. The comprehensive approach—whole exome and whole transcriptome at scale—remains the core differentiator, now extended to whole genome for detection. With a strong balance sheet ($793M cash) and a commitment to shareholder returns (a new $100M buyback), Caris is well-positioned to fund its next catalysts while maintaining profitability.